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Yolanda Sáenz,4 and Francisco Javier Castillo1,2
Aim: Active surveillance of plasmid-mediated b-lactamase-producing Enterobacteriaceae (PMBL-E) in fecal car-
riers in the hospital and in the community setting in a non-outbreak period of time. Methods: Patients were
screened for carriage of Enterobacteriaceae resistant to expanded-spectrum cephalosporins and PMBL-E were
characterized (extended-spectrum-b-lactamase [ESBL], plasmid-mediated AmpC b-lactamase [pAmpC], and
carbapenemases) by PCR and sequencing. Results: The prevalence of ESBL and pAmpC carriers was 5.06% and
0.59%, respectively. Overall, CTX-M-like enzymes were the ESBL dominate enzymes (96.15%). The group CTX-
M-9 was the most prevalent (81, 54%) [CTX-M-14 (74, 91.35%), CTX-M-9 (5, 6.17%), CTX-M-24 (1, 1.23%), and
CTX-M-27 (1, 1.23%)] followed by the group CTX-M-1 (64, 42.67%) [CTX-M-15 (42, 65.63%), CTX-M-1 (13,
20.31%), CTX-M-32 (8, 12.5%), and CTX-M-3 (1, 1.56%)]. One CTX-M-10, one CTX-M-59, and three CTX-M-8
were also found. A very small representation of SHV or TEM ESBL enzymes was found (3.2% and 0.64%,
respectively). pAmpC characterization revealed a predominance of CMY-2 (81.25%), followed by DHA-1
(18.75%). We did not detect the presence of carbapenemase producers. Conclusions: The prevalence of ESBL-
producers from fecal carriers is stable in our area, but colonization by pAmpC producers has emerged recently
as we have confirmed. Periodic active surveillance is useful to identify these human reservoirs and control the
evolution of PMBL carriage in a community over time.
Introduction
The emergence of plasmid-mediated b-lactamase-producing Enterobacteriaceae (PMBL-E) is a great health
concern.17 Active surveillance of PMBL-E fecal carriage is
suggested for hospital infection control, but only a few re-
ports evaluated the fecal carriage of PMBL-E in the com-
munity setting.20,21 Earlier colonization is a known risk factor
for extended-spectrum-b-lactamase (ESBL) Enterobacteriaceae
infections.6 Among ESBL, CTX-M enzymes are the major
concern because they have been spread worldwide, in the
community setting as well as in hospitals.4 Intestinal colo-
nization seems the cornerstone of their dissemination, where
plasmids carrying CTX-M enzymes can disseminate between
Escherichia coli and other commensal enterobacteria.1 There
are little data about the rates of other PMBL-E fecal carriers
as plasmid-mediated AmpC b-lactamases (pAmpCs) or car-
bapenemases in the hospital and community setting.7,10 The
objective of this work was to characterize the PMBL-E (ESBL,
pAmpC, and carbapenemases) present in fecal carriers in a
hospital and in a community setting in a non-outbreak pe-
riod of time.
Materials and Methods
The study was performed at the University Teaching
Hospital ‘‘Lozano Blesa’’ (Zaragoza, Spain), which has 803
beds and serves a population of 286,774 inhabitants, with
29,506 annual admissions. It includes an outpatient care fa-
cility that has 2,315,197 annual visits and an emergency de-
partment that has 127,694 annual visits.
During a 6-month prospective study ( January 2010–June
2010), a total of 3,695 fecal samples from 2,508 patients (of all
the patients who were requested for a stool culture, most of
them were suffering from gastroenteritis) were analyzed
(71.61% of whom were outpatients). The same patients could
be re-enrolled only when a positive culture (Enterobacteriaceae
isolates with a PMBL enzyme) was identified ‡ 30 days from
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the initial enrolment. The stool samples were cultured using
standard methods for Salmonella, Shigella, Campylobacter, Yer-
sinia, Aeromonas, and Plesiomonas.2 One hundred and seventy-
five isolates belonging to the Enterobacteriaceae family grew in
the modified charcoal-cefazolin-deoxycholate agar (CCDA)
containing cefoperazone 32 mg/L and amphotericin B sup-
plement (Oxoid, Basingstoke, United Kingdom) incubated 48
hours under microaerobic conditions and used routinely in
our laboratory for the isolation of Campylobacter spp. All the
Enterobacteriaceae isolated from the CCDA medium were
identified according to classical biochemical methods13 and
screened phenotypically for extended spectrum-b-lactamase
(ESBL), plasmid-mediated AmpC (pAmpC), and carbapene-
mase production. More than one isolate from the same patient
were also studied when different susceptibilities or different
identifications were observed. ESBL production was studied
using the CLSI confirmatory test3 and/or E-test ESBL (AB
Biodisk, Solna, Sweden). pAmpC production was tested by
the E-test with cefotetan/cefotetan-cloxacillin8 and carbape-
nemase production by testing susceptibility to ertapenem
(10mg disc), using a modified Hodge test,15 determining the
minimal inhibitory concentration (MIC) by E-test MBL IP/IPI
(AB Biodisk) and showing synergism with dipicolinic acid,
boronic acid, and cloxacillin 500mg (Rosco Diagnostica,
Taastrup, Denmark). The strains suspected of carrying a re-
sistance pattern compatible with hyperproduction of the
chromosomal enzymes (eight Morganella morganii strains)
were disregarded. Finally, 167 isolates with a PMBL pheno-
type were selected from 142 patients.
Resistance genes, including blaCTX-M consensus, blaCTX-M-1
group, blaCTX-M-9 group, blaCTX-M-10, blaCTX-M-8, blaSHV, and
blaTEM were amplified with specific primers according to
phenotypic results as described elsewhere.5,11,14 Cephalos-
porinase blaCMY and blaDHA were investigated using multiplex
PCR, including the six families of blaAmpC.
16 Amplification
products were sequenced and submitted to the library of the
National Center for Biotechnology Information for identifica-
tion (http://blast.ncbi.nlm.nih.gov). Positive and negative
controls were included in all PCR assays.
Statistical significance was calculated for comparison of
proportions using the chi-square test, and a p-value of < 0.05
was considered statistically significant (SPSS V15.0; SPSS,
Chicago, IL).
Results
A total of 167 Enterobacteriaceae isolates with a PMBL
phenotype from 142 patients were included in the study, 151
of them showed an ESBL phenotype, and in the remaining 16
isolates, a pAmpC phenotype was detected. One hundred
and fifty-six blaESBL genes were detected in the 151 ESBL-
producing isolates of the 3,695 analyzed fecal samples
(4.08%), resulting in a prevalence of ESBL carriers of 5.06%.
Five ESBL-producing isolates presented two different ESBLs.
The 151 ESBL-producing isolates were isolated from hospital
patients (42, 5.89% of hospitalized patients) or outpatients
(85, 4.73% of outpatients) from individuals in the following
age groups: £ 14 years (53, 41.73%), 15–25 years (7, 5.51%),
26–50 years (26, 20.47%), 51–65 years (11, 8.66%), and > 65
years (30, 23.63%).
The most frequent species isolated among the ESBL pro-
ducers were E. coli (141, 93.37%), followed by Klebsiella
pneumoniae (8, 5.29%) and Klebsiella oxytoca (2, 1.32%). Of the
156 ESBL detected, the most frequent were the CTX-M en-
zymes (150, 96.15%) followed by ESBL SHV (5, 3.2%) and
ESBL TEM (1, 0.64%). The group CTX-M-9 was the most
prevalent (81, 54%) [CTX-M-14 (74, 91.35%), CTX-M-9 (5,
6.17%), CTX-M-24 (1, 1.23%), and CTX-M-27 (1, 1.23%)] fol-
lowed by the group CTX-M-1 (64, 42.67%) [CTX-M-15 (42,
65.63%), CTX-M-1 (13, 20.31%), CTX-M-32 (8, 12.5%), and
CTX-M-3 (1, 1.56%)]. One CTX-M-10, one CTX-M-59, and
three CTX-M-8 were also found. The association with other
b-lactamases was studied in resistant strains to cefotaxime
and ceftazidime. CTX-M-15 was detected alone (19, 45.2%) or
in association with other ESBL SHV [SHV-2a (2), SHV-76 (1),
SHV-108 (1)] and/or with other b-lactamases genes: TEM-1
(23), SHV-1 (1). One CTX-M-8 was associated with an ESBL
TEM (TEM-52) and one ESBL SHV (SHV-12) was found
alone. The characterized ESBL enzymes among hospital pa-
tients and outpatients are shown in Table 1. The results re-
vealed that CTX-M-15 and CTX-M-14 were the two most
prevalent enzymes in both patient groups. In hospital
Table 1. Characterization of PMBL Enzymes
Among 167 Strains Isolated from Hospital
Patients and Outpatients in Fecal Flora
Outpatient

















pAmpC (7, 6.42%) CMY-2 (7)
Klebsiella pneumoniae (2) ESBL (3, 2.75%) CTX-M-14 (1)
CTX-M-15 (1)
SHV-108 (1)
Klebsiella oxytoca (2) ESBL (2, 1.83%) CTX-M-14 (1)
CTX-M-10 (1)
Hospital patient
isolates (n = 59)
Type of PMBL
(63, 36.63%)









pAmpC (9, 14.29%) CMY-2 (6)
DHA-1 (3)
K. pneumoniae (6) ESBL (9, 14.29%) CTX-M-15 (6)
SHV-2a (2)
SHV-76 (1)
PMBL, plasmid-mediated-b-lactamase; ESBL, extended-spectrum-
b-lactamase; pAmpC, plasmid-mediated AmpC b-lactamase.
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patients, the prevalence of CTX-M-15 was higher than in
outpatients (2.81% and 1.22%, respectively, p 0.005), whereas
there was no significant difference in the prevalence of CTX-
M-14 (2.67% and 3.06%, respectively, p 0.599).
pAmpC-producing isolates were detected in 16 of the
3,695 fecal samples analyzed (0.43%), all E. coli. These 16
isolates were harbored by 15 patients resulting in a 0.60%
prevalence of pAmpC carriers.
The 16 pAmpC-producing strains were isolated from
hospital patients (8, 1.12% of hospitalized patients) or out-
patients (7, 0.39% of outpatients), from individuals in the
following age groups: £ 14 years (3, 20%), 15–25 years (1,
6.67%), 26–50 years (3, 20%), 51–65 years (1, 6.67%), and > 65
years (7, 46.67%). Of the 16 pAmpC-producing isolates, the
most frequent was the CMY-2 enzyme (81.25%) followed by
the DHA-1 enzyme (18.75%). The characterized pAmpC
enzymes among hospital patients and outpatients are shown
in Table 1. The results revealed that CMY-2 was the pre-
dominate enzyme in both patient groups. In hospital pa-
tients, the prevalence of CMY-2 was higher than in
outpatients (0.84% and 0.39%, respectively, p 0.032). Carba-
penemase-producing isolates were not detected.
Discussion
PMBL-E (ESBL, pAmpC, carbapenemases) have emerged
worldwide and have been reported in hospital patients and
in outpatients.7,10 A threatening epidemiological problem is
the dissemination of PMBL-E to healthy people in the com-
munity, which might depend on the frequency of PMBL fecal
carriage as well as on the presence of PMBL-producing or-
ganisms in the food chain.11,20,21 The rates of fecal carriage of
ESBL-producing strains of the Enterobacteriaceae family were
reported and that increased dramatically in our area from
2.3% in 2002 to 7.4% in 2004.2 The prevalence of ESBL pro-
ducers is currently between the two values obtained in the
previous study. Colonization by pAmpC producers has
emerged recently as we have confirmed. Overall, CTX-M-like
enzymes are the dominate ESBL enzymes (96.15%), previ-
ously demonstrated in other countries.10 ESBL characteriza-
tion revealed a predominance of CTX-M-14 (47.43%) and
CTX-M-15 (26.92%) alone or associated with SHV and TEM,
and a small representation of SHV or TEM ESBL enzymes
were found alone. The scarce presence of TEM and SHV
ESBL in intestinal carriers is surprising since they are not
uncommon in clinical strains in Spain: SHV-12-producing
E. coli remained an important cause of community-acquired
infection in 2006,5 which seems to indicate differences in the
reservoirs and the spread of different groups of ESBLs.
pAmpC characterization revealed a predominance of CMY-2
(81.25%), followed by DHA-1 (18.75%). This distribution is
similar to that found in patients with clinical infections iden-
tified in our environment.9 No carbapenemase-producing
enterobacteria were detected. These strains are identified very
sporadically in the enterobacteria of clinical origin in our
area.12 The emergence of pAmpC is worrisome, because they
appear to follow the same paths as ESBL although there may
be some subtle differences.19 As outpatients could be a res-
ervoir not only of ESBL strains, but also of pAmpC producers,
it suggests the possibility of their widespread emergence too
within the community in the next few years. A high rate has
been demonstrated of intestinal colonization of patients with
community-acquired infections (i.e., abdominal and urinary
tract infection) due to ESBL-producing organisms, considering
intestinal colonization a risk factor for infections with these
bacteria.20 The dynamics of gut pAmpC-producing E. coli as
potentially pathogenic could be similar to ESBL-producing
E. coli, where urinary tract infections accounted for 60% of all
infections caused by pAmpC producers in our country.18
Periodic active surveillance is useful to identify these com-
munity human reservoirs and control the evolution of PMBL
carriage in a community over time.
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zalo, N. Borrell, G. Bou, M.C. Conejo, V. Pomar, B. Aracil,
N. Larrosa, J. Aguero, A. Oliver, A. Fernández, J. Oteo, A.
Pascual, and F. Navarro. 2012. Colonisation and infection
due to Enterobacteriaceae producing plasmid-mediated
AmpC beta-lactamases. J. Infect. 64:176–183.
19. Sidjabat, H.E., D.L. Paterson, Z.A. Qureshi, J.M. Adams-
Haduch, A. O’Keefe, A. Pascual, J. Rodrı́guez-Baño, and Y.
Doi. 2009. Clinical features and molecular epidemiology of
CMY-type beta-lactamase-producing Escherichia coli. Clin.
Infect. Dis. 48:739–744.
20. Valverde, A., F. Grill, T.M. Coque, V. Pintado, F. Baquero,
R. Cantón, and J. Cobo. 2008. High rate of intestinal colo-
nization with extended-spectrum-beta-lactamase-producing
organisms in household contacts of infected community
patients. J. Clin. Microbiol. 46:2796–2799.
21. Valverde, A., T.M. Coque, M.P. Sánchez-Moreno, A.
Rollan, F. Baquero, and R. Cantón. 2004. Dramatic increase
in prevalence of fecal carriage of extended-spectrum beta-
lactamase-producing Enterobacteriaceae during nonoutbreak




Hospital Clı́nico Universitario ‘‘Lozano Blesa’’
and Universidad de Zaragoza




304 GARRIDO ET AL.
